The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for ...
The fair value estimate for Ionis Pharmaceuticals has shifted from US$96.73 to US$100.92, a modest reset that puts fresh numbers around the stock. This move comes during an active period of Street ...
On a mission to expand its recently approved Tryngolza beyond the rare genetic disorder familial chylomicronemia syndrome (FCS), Ionis recently tested its medicine in patients with moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results